Nintedanib Zentiva (Nintedanib)

Nintedanib blocks several receptor tyrosine kinases—VEGFR, FGFR and PDGFR—thereby reducing fibroblast activity, extracellular matrix formation, and new blood‑vessel growth. This multi‑target inhibition curtails the processes that lead to tissue scarring in fibrotic lung disease and limits angiogenesis that supports tumor development.

The dosage of Nintedanib Zentiva is determined by the prescribing physician based on the specific indication, patient characteristics and clinical response. Healthcare professionals follow approved labeling and adjust the regimen as needed; patients should follow the exact instructions provided by their prescriber.

Safety of Nintedanib Zentiva in pregnancy or while breastfeeding has not been established. The product is generally avoided in these populations, and clinicians should discuss potential risks and alternative therapies with women of child‑bearing potential before initiating treatment.

To request Nintedanib Zentiva, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Nintedanib differs from other antifibrotics such as pirfenidone by targeting a broader spectrum of tyrosine kinases, offering both anti‑fibrotic and anti‑angiogenic effects. Clinical data suggest comparable efficacy in slowing lung function decline, but safety profiles and tolerability may vary, making individual patient factors important when selecting therapy.

Nintedanib Zentiva should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct light, and avoid storing them in areas with high humidity or temperature fluctuations to maintain product stability.

Nintedanib Zentiva is taken orally, usually with food to reduce gastrointestinal discomfort. Patients swallow the tablet whole with a glass of water and should follow the timing and dosing schedule prescribed by their healthcare provider, who may adjust the regimen based on clinical response and tolerability.

The most serious risks include severe liver injury, arterial thromboembolic events, major bleeding, gastrointestinal perforation, and rare cases of pneumothorax. Patients should be monitored regularly for signs of hepatic dysfunction, bleeding, or new respiratory symptoms, and any concerning events should prompt immediate medical evaluation.

Nintedanib Zentiva is contraindicated in patients with severe hepatic impairment, uncontrolled bleeding disorders, or known hypersensitivity to the drug. Caution is also advised for individuals taking strong CYP3A4 inhibitors, anticoagulants, or those with significant renal dysfunction, and it should be avoided during pregnancy and lactation.